2-((2R)-2-methylpyrrolidin-1-yl)ethan-1-ol | 379229-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-((2R)-2-methylpyrrolidin-1-yl)ethan-1-ol
• 英文别名: (R)-2-(2-methylpyrrolidin-1-yl)ethanol；2-[(2R)-2-methylpyrrolidin-1-yl]ethanol
• CAS: 379229-46-6
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: CTINRKGSNIHQMR-SSDOTTSWSA-N

物化性质

• 沸点：
  197.8±13.0 °C(Predicted)
• 密度：
  0.958±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((2R)-2-methylpyrrolidin-1-yl)ethan-1-ol 在 钯 偶氮二甲酸二异丙酯 、 四丁基氟化铵 、 甲酸铵 、 溶剂黄146 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 (2S,3R)-3-(4-Hydroxy-phenyl)-2-{4-[2-((R)-2-methyl-pyrrolidin-1-yl)-ethoxy]-phenyl}-2,3-dihydro-benzo[1,4]oxathiin-6-ol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers

  摘要：

  A series of dihydrobenzoxathiin SERAMs with alkylated pyrrolidine side chains or alkylated linkers was prepared. Minor modifications in the side chain or linker resulted in significant effects on biological activity, especially in uterine tissue.

  DOI：

  10.1016/j.bmcl.2004.10.036
• 作为产物：
  描述：

  2-甲基吡咯烷 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 2-((2R)-2-methylpyrrolidin-1-yl)ethan-1-ol
  参考文献：
  名称：

  Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers

  摘要：

  A series of dihydrobenzoxathiin SERAMs with alkylated pyrrolidine side chains or alkylated linkers was prepared. Minor modifications in the side chain or linker resulted in significant effects on biological activity, especially in uterine tissue.

  DOI：

  10.1016/j.bmcl.2004.10.036

文献信息

• 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT
  申请人：Hashimoto Noriaki

  公开号：US20080090799A1

  公开（公告）日：2008-04-17

  Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity. R 1 and R 2 each independently represent a lower alkyl group; X 1 represent a group of a formula (II-1): wherein: R 11 and R 12 each independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, R 11 and R 12 may form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH 2 ) m , R 11 and R 12 may form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

  公开了一种化合物(I)及其药用可接受的盐。这些化合物具有激活葡萄糖激酶的作用，因此可用于治疗糖尿病和肥胖。R1和R2分别独立表示较低的烷基基团；X1表示一个公式(II-1)的基团：其中：R11和R12分别独立表示氢原子或较低的烷基基团，或者与它们结合的氮原子一起，R11和R12可以形成一个4-至7-成员的含氮脂肪环（构成4-至7-成员的含氮脂肪环的一个碳原子可以被氧原子替代），或者与(CH2)m中的一个碳原子一起，R11和R12可以形成一个4-至7-成员的含氮脂肪环；m表示一个从1到3的整数。
• N-PYRAZOLE-2-PYRIDINECARBOXAMIDE DERIVATIVE
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：EP2236507A1

  公开（公告）日：2010-10-06

  The present invention relates to a compound represented by the formula: or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently a lower alkyl group, X is CH or the like, and X1 is an aminoalkoxy group or the like, which has a glucokinase-activating effect and thus is useful in the treatment of diabetes, obesity, and the like.

  本发明涉及一种化合物，其表示为以下结构式：或其药用可接受盐，其中R1和R2各自独立地为较低的烷基基团，X为CH或类似物，X1为氨基烷氧基团或类似物，具有激活葡萄糖激酶的作用，因此在糖尿病、肥胖等疾病的治疗中是有用的。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2002016352A1

  公开（公告）日：2002-02-28

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R?1, n, R2 and R3¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有在说明书中定义的任何含义；它们的制备过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂治疗和/或治疗实体瘤疾病的药物中的使用。
• [EN] QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS<br/>[FR] DERIVES DE LA QUINAZOLINE POUR LE TRAITEMENT DE TUMEURS
  申请人：ASTRAZENECA AB

  公开号：WO2001094341A1

  公开（公告）日：2001-12-13

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, m, R?1, R2, R3 and Q2¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹唑啉衍生物，其中Q1，Z，m，R?1，R2，R3和Q2¿中的每一个都具有描述中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们在制造用于抗侵袭剂的药物，用于包含和/或治疗实体肿瘤疾病。
• Quinazoline derivatives for treatment of tumours
  申请人：——

  公开号：US20040214841A1

  公开（公告）日：2004-10-28

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Q 1 , Z, m, R 1 , R 2 , R 3 and Q 2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 1

  本发明涉及公式（I）的喹嗪衍生物，其中Q1、Z、m、R1、R2、R3和Q2中的每个都具有描述中定义的任何含义；制备它们的过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂以限制和/或治疗实体肿瘤疾病的药物中的使用。